公司深度研究 | 健康元 呼吸龙头再起航，创新+国际化开启成长新篇章 健康元（600380.SH）首次覆盖报告 大型综合医药集团，创新+国际化开启新篇章。公司始创于 1992 年，保健品 业务起家，通过收并购不断开拓商业版图，经过 30 余年逐步发展为大型综 合医药集团。近年来，公司加快布局国际化及创新转型，一方面推动海外生 产基地建设，同时通过合作引进等方式快速丰富研发管线，聚焦呼吸常见疾 病，同时拓展镇痛、抗感染等领域布局。 制剂集采压力出清，新品放量助力主业拐点向上。近年来受艾普拉唑系列产 品、盐酸左沙丁胺醇吸入溶液等大单品降价影响，公司主业短暂承压，目前 核心产品降价压力基本出清，后续随着妥布霉素吸入溶液、玛帕西沙韦等新 品陆续放量，公司主业有望拐点向上。 加快创新管线布局，聚焦呼吸大适应症。多年深耕呼吸领域，近年来随着公 司创新转型进程加速推进，公司通过合作引进快速扩充在研管线，覆盖支气 管扩张、流感、COPD 等呼吸常见适应症。目前改良新药妥布霉素吸入溶液 以及流感新药玛帕西沙韦胶囊已获批，另外 TSLP 单抗、MABA 双靶点吸入 溶液、PREP 抑制剂等核心药物已进入 2 期临床。 丽珠集团： ...

Core Viewpoint - Huaguang New Materials plans to establish a production base in Thailand to enhance its competitiveness and tap into overseas markets, particularly in the refrigeration, electrical, new energy vehicles, and electronics sectors [1][2][4]. Group 1: Company Overview - Huaguang New Materials, founded in 1995, has become a leading enterprise in the domestic brazing materials industry over 30 years of continuous innovation [2][5]. - The company aims to achieve an annual revenue of over 2 billion yuan for the first time in 2025 [2]. Group 2: Financial Performance - For the first three quarters of 2025, Huaguang New Materials reported a revenue of 1.826 billion yuan, a year-on-year increase of 33.15%, and a net profit attributable to shareholders of 158 million yuan, up 100.79% [1][6]. - The company’s revenue for 2023 and 2024 is projected to be 1.415 billion yuan and 1.918 billion yuan, reflecting year-on-year growth of 15.96% and 35.52%, respectively [6]. Group 3: Investment and Expansion Plans - The total investment for the Thailand project is 249 million yuan, with 199 million yuan raised through a specific stock issuance to fund the second phase of the production base [2][3]. - The project aims to add a production capacity of 3,500 tons of brazing materials, including silver, copper, tin, and aluminum-based materials, over a construction period of 2.5 years [3][4]. Group 4: Market Strategy - The company is actively expanding its overseas market presence, particularly in Southeast Asia, to align with its downstream customers who are establishing production bases abroad [2][4]. - Huaguang New Materials is focusing on emerging sectors such as new energy vehicles and electronics, which have shown significant revenue growth, with increases of 75.92% and 50.01% respectively in recent periods [7].

Group 1 - The company is planning to issue overseas shares (H-shares) and list on the Hong Kong Stock Exchange to enhance its international strategic layout [1] - The initiative aims to improve the company's brand international influence and diversify financing channels through international capital markets [1] - This move is part of the company's efforts to support high-quality development [1]

智通财经APP讯，伯特利(603596.SH)发布公告，为深化国际化战略布局，完善海外产能布局，提升公 司品牌国际影响力，积极借助国际资本市场拓展多元化融资渠道，助力公司高质量发展，公司正在筹划 发行境外股份(H股)并在香港联合交易所有限公司(简称"香港联交所")上市事宜。 ...

Core Viewpoint - Yuchai is actively implementing its international development strategy in response to the Belt and Road Initiative, achieving over 50% year-on-year growth in overseas engine sales, marking a significant milestone in its global competitiveness and international strategy [3][4]. Strategic Leadership: Global Layout Reaches New Heights - In 2025, Yuchai deepens its overseas strategy under a new development pattern, focusing on "technology leadership, product diversification, close service, and win-win cooperation" [3]. - The company establishes a multi-dimensional market strategy to consolidate its presence in Asia, deepen its engagement in Africa, break into Europe and the Americas, and expand into emerging markets [3]. Market Expansion: Diverse Channels Build Competitive Barriers - Yuchai's overseas sales channel construction has achieved a qualitative leap, moving beyond traditional agency models to a four-in-one channel system of direct sales, agency, strategic cooperation, and digital platforms [6]. - The company has established solid export partnerships with major domestic truck and bus manufacturers, enhancing its overseas market expansion [6]. Product Innovation: Technology-Driven Global Customer Trust - Yuchai has established a European R&D center and increased its R&D investment, translating these efforts into competitive advantages in overseas markets [9]. - The company has launched several new generation power products that meet international emission standards, gaining recognition from overseas customers [10].

Core Insights - In 2025, China's innovative drug sector is experiencing a significant surge, with 43 innovative drugs approved in the first half of the year, nearing the total approvals for 2024 [1] - China now accounts for approximately one-quarter of the global innovative drug development pipeline, conducting around 3,000 clinical trials annually, placing it at the forefront globally [1] - The total amount for licensing agreements of Chinese innovative drugs has surpassed $100 billion in the first three quarters of 2025, indicating a strong market enthusiasm for domestic innovations [1] - Leading company Heng Rui has established itself as a key player in the innovative drug landscape, focusing on unmet clinical needs and leveraging new technologies for better patient service [1][2] Industry Overview - The Chinese innovative drug industry is reshaping the global biopharmaceutical landscape, transitioning from a "Fast-follower" role to a "First-in-class" and "Best-in-class" approach, led by companies like Heng Rui [2] - The approval speed and quality of innovation in China have significantly improved, with a nearly 60% year-on-year increase in new drug approvals in the first half of 2025 [3] - China has become a major source of global pharmaceutical innovation, with the number of new drug molecules designed in China surpassing those from Europe and the U.S. for the first time in 2024 [3] Heng Rui's Strategy - Heng Rui's innovation strategy focuses on three key areas: patient-centered needs, modular-driven differentiation, and comprehensive chronic disease management [4] - The company is expanding its research platforms to include various advanced technologies such as ADCs, bispecific antibodies, and small nucleic acid drugs, while continuously optimizing these platforms [4] - In oncology, Heng Rui is developing a "four-in-one" collaborative innovation therapy system that encompasses precision therapy, immunotherapy, targeted chemotherapy, and supportive care [5] Global Expansion - By 2025, Chinese innovative drugs accounted for over 20% of global licensing transactions, reflecting a shift in confidence towards China's biopharmaceutical capabilities [6] - Heng Rui has achieved significant milestones in business development (BD), with total licensing agreements exceeding $28 billion over the past three years, partnering with major multinational corporations [6][8] - A notable collaboration with GlaxoSmithKline (GSK) involved a record-breaking licensing deal for 12 innovative projects, highlighting the growing recognition of Chinese companies' research capabilities [7] Future Outlook - Heng Rui anticipates over 10 innovative drugs and approximately 20 new indications to be approved domestically within the next two years, while also exploring new BD transactions and enhancing global clinical capabilities [8] - The Chinese innovative drug sector is expected to see a wave of projects launched in major global markets, accelerating the globalization of domestic companies [10] - Heng Rui's transformation is attributed to sustained high R&D investment, with a research expense ratio reaching 30%, and a robust pipeline of over 100 innovative products in clinical development [11]

公告显示，聚和材料本次发行H股并上市尚需提交公司股东会审议，在符合中国境内相关法律、法规和 规范性文件、中国香港法律的要求和条件下进行，并需取得中国证券监督管理委员会、香港证券及期货 事务监察委员会和香港联交所等相关政府机构、监管机构备案、批准和/或核准。截至目前，公司正与 相关中介机构就本次发行H股并上市的相关工作进行商讨，除本次董事会审议通过的相关议案外，其他 关于本次发行H股并上市的具体细节尚未最终确定。 资料显示，聚和材料创立于2015年，2022年12月9日登陆A股科创板。目前，聚和材料已成为全球领先 的光伏导电浆料科技企业。此外，在半导体、新能源汽车和电子浆料等非光伏领域，聚和材料也通过创 新的研发理念和高效快速的协作研发，持续不断为市场和客户提供定制化的技术和解决方案。2025年上 半年，聚和材料实现营业收入64.35亿元，同比下滑5%，净利润1.81亿元，同比下滑40%；其中，2025 年单二季度实现营业收入10.42亿元，环比增长4%，净利润9100万元，环比增长2%，业绩主要由光伏导 电浆料板块贡献。 12月22日晚，聚和材料(688503)公告，公司于2025年12月19日召开第四届董事 ...

聚和材料（证券代码：688503）于2025年12月23日发布提示性公告，宣布公司正筹划首次公开发行H股 股票并在香港联合交易所有限公司主板上市。公告显示，公司已于2025年12月19日召开第四届董事会第 十一次会议，审议通过了《关于公司首次公开发行H股股票并在香港联合交易所有限公司上市的议案》 《关于公司首次公开发行H股股票并在香港联合交易所有限公司上市方案的议案》等相关议案，本次发 行H股并上市事项尚需提交公司股东会审议，且公司将在股东会审议通过之日起24个月内选择适当的时 机和发行窗口完成本次发行；本次筹划香港上市主要目的为满足公司国际化战略及海外业务布局需要， 提升公司国际品牌知名度，增强公司综合竞争力；截至目前，公司正与相关中介机构就本次发行H股并 上市的相关工作进行商讨，但拟发行股份比例等具体细节尚未最终确定。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨 ...

Core Viewpoint - Nanhua Futures has officially listed on the Hong Kong Stock Exchange, achieving a dual listing in both A and H shares, marking a significant milestone in its internationalization strategy [1][3]. Group 1: Listing and Financial Details - The global offering of H shares consisted of 108 million shares, with 16.15 million shares allocated for public offering in Hong Kong and 91.51 million shares for international offering. The estimated net proceeds from the global offering are approximately HKD 1.203 billion after deducting related underwriting commissions and other estimated expenses [1]. Group 2: Internationalization Strategy - The listing is a result of Nanhua Futures' long-term commitment to internationalization, with subsidiaries established in key global markets such as Hong Kong, the United States, Singapore, and the United Kingdom, creating a diversified overseas business matrix covering futures, securities, and asset management [2]. - As of June 30, 2025, the overseas financial services segment has become a core growth engine, contributing 48.3% of total operating revenue in 2024 and increasing to 55.1% in the first half of 2025. The company has accumulated approximately 2,077 registered enterprise clients in its overseas business [2]. Group 3: Industry Impact and Competitive Advantage - The dual listing addresses the long-standing issue of homogeneous competition in the domestic futures industry, positioning Nanhua Futures for differentiated development and serving as a replicable model for leading futures companies expanding internationally [3]. - This strategic move is expected to accelerate the concentration of industry resources towards high-quality entities, enhancing industry concentration and driving the sector into a new phase characterized by "service deepening + capital empowerment" [3]. Group 4: Compliance and Risk Management - Nanhua Futures prioritizes compliance and risk management as its core operational foundation, holding the highest AA rating in domestic regulatory assessments, reflecting strong recognition from regulatory bodies for its stable operations and governance [4]. - The company has a comprehensive licensing system, including being one of the first full clearing members of the China Financial Futures Exchange, which supports its ability to navigate complex market environments [4]. Group 5: Financial Performance - In 2024, the company achieved operating revenue of CNY 5.712 billion and a net profit attributable to shareholders of CNY 458 million, representing a year-on-year growth of 13.96%, demonstrating resilience amid an overall decline in industry net profits [5]. - For the first half of 2025, the company reported a net profit of CNY 231 million, showcasing strong operational resilience despite market volatility, and maintained a net profit of CNY 351 million for the first nine months of 2025, remaining stable compared to the previous year [5].

Group 1: Market Development and Strategy - The company views incremental business as a key source for development and expansion, despite increasing competition in the market [2] - The international market, particularly in the oil and petrochemical sectors, presents significant growth opportunities, especially with increased investment and project acceleration in the Middle East [2] - The company aims to capture market share in the international stock market by gradually replacing foreign brands with its products, focusing on "occupying stock through incremental" strategies [3] Group 2: Product and Service Quality - The company has over 40 years of development, achieving industry-leading technology levels, which allows it to replace foreign mechanical seals in key application areas [3] - A strong service attitude and efficient problem-solving enhance customer trust and loyalty, particularly after resolving critical issues [3] - The mechanical seal industry faces challenges due to its complex nature, requiring high levels of expertise and experience, with past engineering performance being a significant barrier to entry [3] Group 3: International Expansion - The acquisition of the German subsidiary KS GmbH is a strategic move to enhance international market presence and gain valuable experience in international mergers and acquisitions [3] - KS GmbH's products are at an internationally leading level, providing synergy with the company's existing operations [3]